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During a screen for humoral factors that promote
cardiomyocyte differentiation from embryonic stem
cells (ESCs), we found marked elevation of granulo-
cyte colony-stimulating factor receptor (G-CSFR)
mRNA in developing cardiomyocytes. We confirmed
that both G-CSFR and G-CSF were specifically ex-
pressed in embryonic mouse heart at the midgesta-
tional stage, and expression levels were maintained
throughout embryogenesis. Intrauterine G-CSF
administration induced embryonic cardiomyocyte
proliferation and caused hyperplasia. In contrast,
approximately 50% of csf3r–/– mice died during late
embryogenesis because of the thinning of atrioven-
tricular walls. ESC-derived developing cardiomyo-
cytes also strongly expressed G-CSFR. When
extrinsic G-CSF was administered to the ESC- and
human iPSC-derived cardiomyocytes, it markedly
augmented their proliferation. Moreover, G-CSF-
neutralizing antibody inhibited their proliferation.
These findings indicated that G-CSF is critically
involved in cardiomyocyte proliferation during devel-
opment, and may be used to boost the yield of cardi-
omyocytes from ESCs for their potential application
to regenerative medicine.
INTRODUCTION
Embryonic stem cells (ESCs) are one of the most attractive stem
cell populations for potential use in establishing regenerative
medical procedures. ESCs have an unlimited proliferation
capacity and promising multipotency. Although the use of
human ESCs is still disputed ethically and legally because of their
origin, these issues may potentially be circumvented by the use
of induced pluripotent stem cells (iPSCs) that are not embryo
derived and that have been established in mice and humans(Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Yu
et al., 2007). iPSCs are an excellent candidate for stem cell-
based cell replacement therapy: they have a differentiation
capacity similar to that of ESCs. However, to realize the potential
of using ESCs or iPSCs in regenerative medicine and using this
to treat many incurable cardiac diseases, we must first establish
a highly efficient differentiation system.
Cardiomyocyte development is a multistep process that
involves initial mesodermal differentiation, emergence of the
cardiac myoblast, cardiac myoblast proliferation, and cardio-
myocyte maturation. We reported previously that BMP (bone
morphogenetic protein) antagonist noggin induced cardiomyo-
cyte differentiation from ESCs by influencing cardiac commit-
ment of mesodermal progenitor cells (Yuasa et al., 2005). In order
to establish a more efficient cardiomyocyte differentiation sys-
tem, we used microarray analysis to screen humoral factors by
comparing noggin-treated ESC-derived cardiomyocytes and
nontreated control ESCs. We confirmed that the upregulation of
many humoral factors could not induce ESCs to differentiate
into cardiomyocytes efficiently. We assumed that any upregu-
lated genes could be associated with cardiomyocyte differentia-
tion and that any additional factors could not drastically increase
cardiomyocyte differentiation. Next, we searched for receptors
that were upregulated in the cardiomyocyte differentiation group,
based on the hypothesis that these ligands might efficiently
promote cardiomyocyte differentiation. We found that the
expression level of csf3r, which encodes the granulocyte
colony-stimulating factor receptor (G-CSFR), was significantly
higher in noggin-treated cardiomyocyte differentiating ESCs
than in the control cells. G-CSF is a hematopoietic cytokine (De-
metri and Griffin, 1991; Welte et al., 1996), and its role in hemato-
poiesis and stem cell mobilization has been investigated in detail
(Chen et al., 2006; Morrison et al., 1997). However, little is known
about the role of G-CSF in heart development. To further explore
the roleofG-CSFsignaling in cardiomyocytedevelopmentand its
involvement in the differentiation of ESCs into cardiomyocytes,
we investigated the expression pattern of G-CSFR in vivo and
the effect of G-CSF during cardiomyogenesis in vitro and in vivo.
We show here that embryonic cardiomyocytes abundantly
expressed G-CSFR at approximately embryonic day (E)9.5Cell Stem Cell 6, 227–237, March 5, 2010 ª2010 Elsevier Inc. 227
Figure 1. G-CSF and G-CSFR Are Ex-
pressed in the Developing Heart after Midg-
estation
(A) Whole-mount in situ hybridization for nkx2.5
and G-CSFR. G-CSFR was expressed in the heart
at E9.5.
(B and C) Triple staining for a-actinin, g-scfr, and
DAPI in E9.5 mouse embryos (horizontal section).
G-CSFR (green) is colocalized with a-actinin (red)
in the heart and somite at E9.5.
(D and E) Triple staining for a-actinin, g-scf, and
DAPI in E9.5 mouse embryos (horizontal section).
G-CSF (red) colocalized with a-actinin (green) in
the cardiomyocytes.
(F and G) Quantitative RT-PCR analysis of csf3r
and csf3. cDNA was obtained from the embryonic
hearts. csf3r and csf3 were expressed at E10.0,
and their expression levels were attenuated.
(H) csf3r expression in isolated cardiomyocytes
was detected by quantitative RT-PCR. *p < 0.05
versus ESCs (n = 6).
Cell Stem Cell
G-CSF Promotes Cardiomyocyte Proliferationand that intrauterine G-CSF administration strongly promoted
the proliferation of embryonic cardiomyocytes. Moreover, G-
CSFR gene targeting resulted in fetal death in approximately
50% of samples resulting from the thinning of atrioventricular
walls. Based on these in vivo findings, we applied G-CSF to
our ESC-derived cardiomyocyte differentiation protocol. ESC-
derived developing cardiomyocytes also strongly expressed
G-CSFR 6 days after the initiation of differentiation. Stimulation
with extrinsic G-CSF dramatically increased the number of
ESC-derived cardiomyocytes. In contrast, neutralizing intrinsic
G-CSF with a specific antibody or mitotic inhibitory agent
decreased the number of ESC-derived cardiomyocytes. The
effect of G-CSF is also demonstrated in primate ESCs and
human iPSCs (hiPSCs). These results indicated that G-CSF228 Cell Stem Cell 6, 227–237, March 5, 2010 ª2010 Elsevier Inc.directly regulates cardiomyocyte prolifer-
ation in vitro and in vivo.
RESULTS
G-CSFR Is Expressed
in the Developing Heart
We first investigated the expression
pattern of G-CSFR in developing mouse
hearts. Whole-mount in situ hybridization
revealed no expression of csf3r until E8.5,
strong expression around E9.5, and a
gradual decrease thereafter (Figure 1A).
Immunofluorescent staining demon-
strated G-CSFR expression in the heart,
somite, vascular endothelium, and liver
from E8.5 to E10.5. Expression in the
heart peaked at E9.5 and colocalized
completely with the cardiomyocyte mar-
ker a-actinin but not in the epicardium
(Figure 1B; Figure S1 available online).
G-CSFR was localized to the cell mem-
brane of a-actinin-positive cardiomyo-
cytes (Figure 1C). The G-CSF ligand wasalso expressed in the heart around E9.5 (Figure 1D). G-CSF was
localized to the cytoplasm of a-actinin-positive cardiomyocytes
(Figure 1E). Quantitative RT-PCR confirmed expression of both
G-CSFR and G-CSF in the embryonic heart (Figures 1F and
1G). We purified the E9.5 cardiomyocytes by FACS, analyzed
them by quantitative RT-PCR, and then confirmed that the cardi-
omyocytes themselves expressed both G-CSFR and G-CSF
(Figure 1H; Figure S1B).
G-CSF Strongly Enhances the Proliferation
of Cardiomyocytes
We next injected G-CSF directly into the uterus of pregnant mice
at E9.0 to investigate the function of G-CSF signaling in the
developing heart, and we used the BrdU incorporation assay
Figure 2. Effect of Extrinsic G-CSF Admin-
istration and Gene Targeting of g-scfr on
Heart Development
(A and B) Immunofluorescence staining of the
heart for BrdU and MEF2C. BrdU labeling indices
are shown. G-CSF was injected into the uterus at
E9.0, BrdU was intraperitoneally injected at E9.5,
and heart was obtained at E12.5. Note that
BrdU-positive cells were markedly increased in
G-CSF-administered mice (n = 5) and decreased
in csf3r KO mice (n = 5). BrdU (green) colocalized
with MEF2C (red).
(C and D) Immunofluorescent staining for phos-
pho-histone H3 and its labeling index are shown.
The protocol is described above (n = 5).
(E and F) Effect of extrinsic G-CSF administration
on cultured cardiomyocytes isolated from an
embryonic heart by FACS. Triple staining for
Nkx2.5 (red), BrdU (green), and DAPI (blue) in
cultured cardiomyocytes isolated from embryonic
mice at E9.5. BrdU labeling indices are shown.
G-CSF and BrdU were added to the medium at
the start of culture and the assay was performed
48 hr later. Note that the total cell number and
BrdU-positive cells were markedly increased by
G-CSF administration (n = 11).
(G and H) Cardiomyocytes isolated from E9.5 and
E12.5 embryos and from neonates were stimu-
lated with G-CSF. Total cell numbers per visual
field are shown. Note that G-CSF-mediated cardi-
omyocyte proliferation was greater at E9.5, slight




G-CSF Promotes Cardiomyocyte Proliferationas a readout of function. After intraperitoneal injection of BrdU at
E9.5,embryoswere removedandanalyzedatE12.5.G-CSF injec-
tionmarkedly increased the number of BrdU-positive cardiomyo-
cytes in wild-type mice, but not in csf3r–/– mice. Moreover, they
were lower in number in csf3r–/– mice than in the controls (PBS
injection), suggesting thatG-CSFpromotes cardiomyocyte prolif-
eration (Figure 2A). TheBrdU labeling index, definedas the ratio of
MEF2C/BrdU double-positive nuclei to MEF2C-positive nuclei,
was 2.5 times higher in G-CSF-injected embryonic hearts than
in the controls. G-CSF injection did not increase theBrdU labeling
index in csf3r–/– embryonic hearts (Figure 2B). Furthermore,
G-CSF did not increase BrdU incorporation in other G-CSFR-
negative tissues such as skin and gut (Figure S2). Immunofluores-
cent staining revealed 5-fold more phosphohistone H3 antibody-Cell Stem Cell 6, 227–2positive cardiomyocytes in the G-CSF-in-
jected embryos 6 hr after injection than in
the controls (Figures 2C and 2D). Because
G-CSF has a critical role in preventing
apoptosis of adult cardiomyocyte, we
examined whether G-CSF had antiapop-
totic effect in the developing heart. We
obtained GCSFR-deficient (csf3r–/–) mice
and used them as a negative control.
G-CSF injectiondidn’t affect theapoptotic
index in the wild-type and csf3r–/– embry-
onic hearts (Figures S3A and S3B).To elucidate whether this effect is directly mediated by
G-CSF or indirectly mediated by blood cells or other cells, we
examined the proliferation potential of G-CSF in isolated cardi-
omyocytes. Purified cardiomyocytes obtained from E9.5 and
E12.5 embryonic hearts were stimulated with G-CSF. BrdU
incorporation was then measured and the total cell number
was determined by direct counting. G-CSF markedly increased
both total cell number and the level of BrdU incorporation. The
BrdU labeling index in G-CSF-administered cardiomyocytes
was 2.5 times higher than in the controls (Figures 2E and 2F).
Cell counting revealed that G-CSF-mediated cardiomyocyte
proliferation was greater at E9.5 than in controls, slight at
E12.5, and not evident in the neonatal cardiomyocytes (Figures
2G and 2H).37, March 5, 2010 ª2010 Elsevier Inc. 229
Figure 3. Effect of G-CSF Administration and G-CSFR
KO on Heart Morphology
(A) PBS (negative control) or G-CSF was administered into
the uterus at E9.0, and the hearts were excised from neonates
(n = 12, respectively). Representative photography of the HE
staining was shown. The G-CSF-injected hearts had an
enlarged trabecular layer and thickened compact layer than
controls.
(B and C) PBS or G-CSF was administered to the wild-type
mice or csf3r–/– mice at E9.0. The hearts were excised at
E16.5 (n = 7, respectively). The G-CSF-injected wild-type
(WT) mice hearts had markedly thickened ventricular walls.
However, the G-CSF-injected csf3r–/– mice heart had very
thin ventricular walls. Quantitative analysis of the thickness
of the compact layer and trabecular layer are indicated.
*p < 0.05.
(D) Sections of the neonatal hearts in the wild-type (WT) and
csf3r–/– mice are shown. Note that csf3r–/– mice heart had
thinning of the atrial and ventricular walls (n = 8). LV, left
ventricle; RV, right ventricle; LA, left atrium; RA, right atrium.
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G-CSF Promotes Cardiomyocyte ProliferationNext, we investigated whether the intrauterine administration
of G-CSF at E9.5 could increase the number of cardiomyocytes
in vivo. The heart was sectioned and the ventricular wall thick-
ness was measured at E16.5 or in the day 1 neonate. We found
that G-CSF administration significantly enhanced the ventricular
wall thickness (Figure 3A; *p < 0.05).
We then observed themorphology of the heart in csf3r–/– mice.
The atrial and ventricular walls were significantly thinner in
csf3r–/– mice than in wild-type mice (*p < 0.05). To investigate
more closely the effect of G-CSF on cardiac morphogenesis,
we performed morphometric analysis of the hearts of mice
treated with G-CSF, of csf3r–/– mice at the late embryonic stage,
and of controls (Figures 3B–3D). We showed that the thickness
of both the trabecular and compact layers were increased by
G-CSF administration and decreased by gene targeting of
csf3r. Taken together, these findings demonstrated that G-CSF
strongly enhances the proliferation of cardiomyocytes.
G-CSF Increased Murine ESC-Derived Cardiomyocytes
To clarify whether G-CSF signaling is also pivotal for cardiomyo-
cyte differentiation in vitro, we examined the expression of G-
CSF and its receptor in embryoid bodies (EBs). Immunostaining
showed that noggin-treated, cardiomyocyte-rich EBs contained
more G-CSFR-positive cells than did the untreated controls230 Cell Stem Cell 6, 227–237, March 5, 2010 ª2010 Elsevier Inc.(Figure 4A). Quantitative RT-PCR analysis revealed
faint expression of G-CSFR in the control EBs at
day 6 after EB formation; expression became
evident at day 9 when cardiomyocyte differentia-
tion is typically complete. In contrast, noggin-
treated cardiomyocyte-rich EBs had markedly
high levels of G-CSFR from day 6 (Figure 4B).
Next, we confirmed whether G-CSFR was ex-
pressed in the differentiating cardiomyocytes
by immunostaining for G-CSFR, Nkx2.5, and
a-actinin. G-CSFR was not expressed in the undif-
ferentiated ESCs and was expressed in the cardio-
myocytes of noggin-treated EBs from day 6
(Figures 4C–4E). Immunostaining also showedG-CSF in the cardiomyocytes and surrounding cells of the
treated EBs on day 7 (Figures 4F and 4G), indicating secretion
of the ligand. RT-PCR confirmed the expression of G-CSF on
day 5 in noggin-treated EBs (Figure 4B). These results indicated
that G-CSF acts on cardiomyocytes in both an autocrine and
paracrine manner.
To assess whether G-CSF promotes cardiomyocyte prolifera-
tion, we stimulated mouse ESCs with G-CSF from 4 to 8 days
after removing the leukemia inhibitory factor (LIF) and plating
the cells onto petri dishes. The proportion of spontaneously
beating EBs was counted on day 10 (Figure 5A). G-CSF signifi-
cantly increased the incidence of beating EB, with the optimal
timing occurring on day 6 (Figure 5B). A G-CSF concentration
of 0.75 ng/ml was optimal in terms of efficacy (Figure 5C). We
also examined the effect of G-CSF on undifferentiated ESCs.
Total cell number was not increased by G-CSF on the day of
differentiation induction. G-CSF administration on the day of
differentiation induction did not increase the incidence of beating
EBs (Figures S4A and S4B). EBs treated with G-CSF on day 4, 6,
and 8 after differentiation induction were analyzed by quantita-
tive RT-PCR on day 10 for the presence of transcripts of several
cardiac markers (Figure 5D). All cardiac marker genes were ex-
pressed more strongly in G-CSF-treated EBs. Optimal expres-
sion occurred on days 6, concordant with the beating incidence
Figure 4. G-CSF and G-CSFR Were Ex-
pressed in ESC-Derived Developing Cardio-
myocytes
(A) Immunofluorescent staining for G-CSFR in
mouse embryoid bodies (EBs) at day 6. The
noggin-treated EBs, which contained abundant
cardiomyocytes, strongly expressed G-CSFR,
while the control (noggin-untreated) EBs did not.
(B) Time course of csf3r and csf3 expression in
EBs detected by quantitative RT-PCR. Noggin-
induced, cardiomyocyte-rich EBs expressed
csf3r and csf3 at an earlier stage and at higher
levels compared with the control EBs (n = 7).
(C) Immunostaining for G-SCFR (green) in undiffer-
entiated ESCs.
(D) Triple-immunofluorescent staining for G-CSFR
(green), Nkx2.5 (red), and To-pro3 was demon-
strated on day 6 noggin-treated EBs. Nkx2.5-posi-
tive cells (cardiomyocytes) expressed G-CSFR.
(E) Triple-immunofluorescent staining for G-CSFR
(green), a-actinin (red), and DAPI was demon-
strated on day 7 noggin-treated EBs. Noggin-
treated EBs contained abundant cardiomyocytes,
which also expressed G-CSFR. Lower panels
indicated higher magnification.
(F) Immunofluorescent staining for G-CSF (green)
of the noggin-treated EBs at day 7. Noggin-treated
EBs expressed G-CSF.
(G) Triple-immunofluorescent staining for G-CSF
(green) and MEF2C (red) of the noggin-treated
EBs at day 7 (higher magnification).
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G-CSF Promotes Cardiomyocyte Proliferationassay. To confirm the effect of G-CSF administration on cardio-
myocyte content, we immunostained EBs for cardiomyocyte
markers such as a-actinin, actin, troponin I, myosin light chain
(mlc), myosin heavy chain (mhc), and atrial natriuretic peptide
(anp). Most cells in the G-CSF-treated EBs were immunopositive
for these markers, whereas the controls contained few cardio-
myocytes (Figure 5E). Incubation with an anti-G-CSF neutralizing
antibody to inhibit endogenous G-CSF activity decreased
cardiac marker expression in a dose-dependent manner, con-
firming that the effect was specific to G-CSF (Figure 5F). We
also analyzed cardiomyocytes by immunofluorescence staining
for MEF2C as well as by TUNEL staining in the EBs treated with
or without G-CSF. We found no significant difference in the
apoptotic index between G-CSF-stimulated and untreated car-
diomyocytes (Figure S5; *p < 0.05).
G-CSFAugmented theCardiomyocyteContent in EBs by
PromotingTheir Proliferation via the JAK/STATPathway
To elucidate the critical stage for G-CSF signaling in cardiomyo-
cyte proliferation, we analyzed mesodermal and cardiac marker
gene expression by quantitative RT-PCR. Brachyury T was
already attenuated and Nkx2.5 expression was starting toCell Stem Cell 6, 227–2appear on day 6, the optimal time for
G-CSF administration. G-CSF did not
significantly affect Nkx2.5 expression
on day 7, but dramatically increased
Nkx2.5 expression thereafter (Figure 6A).
These data suggested that G-CSF is not
crucial during the cardiac commitmentof mesodermal progenitor cells but is critically involved in cardi-
omyocyte proliferation. To confirm this hypothesis, we treated
EBs with G-CSF and incubated them with BrdU simultaneously
for 18 hr. We then performed double-immunostaining with
BrdU and MEF2C antibodies. G-CSF-treated EBs showed
striking colocalization of MEF2C and BrdU staining and an over-
all increase in the number of double-positive nuclei. The BrdU
labeling index was also significantly increased by G-CSF. Next,
we generated EBs in the presence of G-CSF and the inhibitors
of proliferation, nocodazole, aphidicolin, and roscovitine. The
BrdU incorporation assay revealed that these inhibitors fully
abrogated the effect of G-CSF (Figures 6B and 6C).
Next, we elucidated the signaling pathway of G-CSF-depen-
dent cardiac progenitor cell proliferation by using the embryonic
stem cell differentiation system. Among the various signaling
inhibitors, only the JAK inhibitor and STAT3 inhibitor almost
completely abolished the effect of G-CSF (Figure 6D). To confirm
the results, we next specifically downregulated the expression of
JAK2 and STAT3 by using two different kinds of siRNAs.
Silencing of both JAK2 and STAT3 also abrogated the effect of
G-CSF (Figures 6E and 6F). We also investigated the effect of
G-CSF on the explant culture of the embryonic hearts at E9.5,37, March 5, 2010 ª2010 Elsevier Inc. 231
Figure 5. G-CSF Increased the Total
Number of ESC-Derived Cardiomyocytes
(A) Diagrammatical representation of the experi-
mental protocol. Differentiating EBs were stimu-
lated with G-CSF on days 4, 5, 6, 7, and 8 after
induction of differentiation. Gene expression anal-
yses were performed on day 10.
(B) Optimal timing of G-CSF treatment of cardio-
myocytes derived from ESCs. Incidence of auton-
omously beating EBs is indicated (n = 20, respec-
tively).
(C) Optimal concentration of G-CSF treatment of
cardiomyocytes derived from ESCs. Incidence of
autonomously beating EBs is indicated (n = 20,
respectively).
(D) Optimal timing of G-CSF administration for
ESC-derived cardiomyocytes was investigated by
quantitative RT-PCR for cardiomyocyte markers.
(E) Immunostaining for cardiac-specific proteins in
G-CSF-treated ESCs.
(F) Neutralizing G-CSF antibody abrogated cardi-
omyocyte marker expression in differentiating
ESCs in a dose-dependent manner (n = 7).
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G-CSF Promotes Cardiomyocyte Proliferationand we found that G-CSF promoted the cell proliferation of early
developing cardiomyocytes through JAK2/STAT3 pathway
(Figure S6). Based on these findings, we conclude that G-CSF
augmented the level of cardiomyocytes in EBs by promoting
their proliferation and that this effect is mediated by the JAK-
STAT signaling pathway.
G-CSF Increased Primate ESC- and Human
iPSC-Derived Cardiomyocytes
To test this effect in primate cardiogenesis, we investigated the
beating incidence of common marmoset ESCs (CMESCs) after
G-CSF administration at various time points. The optimal timing
was day 6 after EB formation, and the difference between
G-CSF-treated and control EBs became evident at day 14232 Cell Stem Cell 6, 227–237, March 5, 2010 ª2010 Elsevier Inc.(Figure 7A). G-CSF stimulation at earlier
or later stages promoted cardiogenesis
to a lesser extent than even the control
levels. This suggested that the effect is
specific to day 6 and thatG-CSF signaling
might therefore promote the differentia-
tion of other cell lineages to decrease
the beating incidence. Immunostaining
showed that G-CSF increased cardiac
troponin I- and Nkx2.5-positive areas in
CMESC-derived EBs (Figure 7B). Next,
to confirm whether G-CSF enhances the
proliferation of early cardiomyocytes in
human pluripotent stem cells, we exam-
ined the effect of G-CSF by using human
iPSC (hiPSC) differentiation system. G-
CSF administration on day 6 significantly
increased the percentage of spontane-
ously beating EBs (Figure 7C). NKX2.5-
positive cells were also significantly
increased by G-CSF administration (Fig-
ure 7D). Furthermore, quantitative RT-PCR also showed that the expression levels of several cardiac
markers were strongly elevated in EBs treated by G-CSF
(Figure 7E). We then immunostained hiPSC-derived EBs for car-
diomyocytemarkers, such as a-Actinin, TroponinC,NKX2.5, and
ANP. It apparently showed thatG-CSF significantly increased the
cardiac marker protein expression in hiPSC-derived EBs
(Figure 7F). These findings indicated that G-CSF acts commonly
on not only mouse but also monkey and human pluripotent stem
cells and enhances the proliferation of early cardiomyocytes.
DISCUSSION
It is well known that ESC differentiation mimics normal develop-
ment. To establish an efficient system for ESC-derived
Figure 6. G-CSF Increased Proliferation in
ESC-Derived Developing Cardiomyocytes
via JAK/STAT Pathway
(A) Quantitative RT-PCR of brachyury T (meso-
dermal marker) and nkx2.5 (early cardiac marker)
in pre-G-CSF (white columns), G-CSF-treated
(gray columns), and control (black columns) cells.
Effect of G-CSF was demonstrated after cardio-
myocyte differentiation.
(B and C) G-CSF administration augmented BrdU
uptake and cell number in ESC-derived differenti-
ating cardiomyocytes (n = 7), and this effect was
abrogated by the mitotic inhibitors, nocodazole
(n = 7), roscovitine (n = 6), and aphidicolin (n = 9).
Triple immunofluorescence staining for MEF2C,
BrdU, and DAPI was examined. BrdU labeling
indices are shown.
(D) The effect of signal inhibitors on BrdU labeling
index in G-CSF-treated cardiomyocytes was
demonstrated with ESC differentiation system
(n = 8). JAK and STAT3 inhibitors significantly
reduced the BrdU labeling index.
(E and F) Specific silencing the expression of JAK2
and STAT3 with two different siRNAs resulted in
significantly reduced the BrdU index in G-CSF-
treated ESC-derived cardiomyocytes (n = 9),
*p < 0.05.
Cell Stem Cell
G-CSF Promotes Cardiomyocyte Proliferationcardiomyocyte differentiation, it was necessary to determine the
physiological mechanisms involved in embryonic heart develop-
ment. Cardiomyocyte development is a multistep process that
includes initial mesodermal induction, emergence of the cardio-
myoblast, cardiomyoblast proliferation, and cardiomyocyte
maturation (Srivastava, 2006). Accumulating evidence has
shown that cardiomyocyte differentiation is precisely regulated
by wnts (Arnold et al., 2000), wnt inhibitors (Schneider and Mer-
cola, 2001), BMPs (Behfar et al., 2002), BMP inhibitors (Yuasa
et al., 2005), hedgehog (Goddeeris et al., 2007), and notch
(Grego-Bessa et al., 2007), with tightly controlled temporal andCell Stem Cell 6, 227–2spatial patterning. Although ESC-derived
cardiomyocyte differentiation methods
have been designed based on these
regulatory factors, none are satisfactorily
efficient. To improve the efficiency of car-
diomyocyte differentiation, we focused
on another step of the differentiation
pathway. Controlling cardiomyocyte
proliferation during development was an
attractive step.
Cardiomyocyte proliferation is one of
the most important physiological steps
in heart development and is regulated
by several growth factors and cytokines
(Olson and Schneider, 2003). Insulin-like
growth factor-1 (IGF-1) and its receptor
(Kajstura et al., 1994; Reiss et al., 1996),
as well as several fibroblast growth
factors and their receptors (Lavine et al.,
2005), regulate myocardial proliferation
during midgestational heart develop-ment. Retinoic acid produced by the epicardium is also a critical
regulator of cardiac growth, and RXRa–/– mice die during
embryogenesis from a failure in the proliferative expansion of
ventricular cardiomyocytes (Sucov et al., 1994; Kastner et al.,
1997). BMP10 is specifically expressed in the ventricular trabec-
ular myocardium from E9.0 to 13.5 and BMP10–/– mice have a
cardiac growth defect (Chen et al., 2004). These factors syner-
gistically regulate cardiomyocyte proliferation under normal
physiological conditions. Therefore we attempted to use these
factors to achieve cardiomyocyte proliferation during ESC differ-
entiation, but we failed to establish an efficient cardiomyocyte37, March 5, 2010 ª2010 Elsevier Inc. 233
Figure 7. G-CSF-Augmented Cardiomyo-
cyte Content in Common Marmoset
Monkey ESCs and Human iPSCs
(A) Panel shows the incidence of spontaneously
beating cells. G-CSF administration on day 6
increased beating cells comparedwith the control.
(B) Immunofluorescent staining shows G-CSF
increased the expression of cardiac troponin I
and nkx2.5 in G-CSF-treated CMESCs compared
to the nontreated control.
(C) Effect of G-CSF on the incidence of the spon-
taneous beating EBs in hiPSCs. G-CSF adminis-
tration significantly increased the incidence of
spontaneous beating EBs compared with the
control (n = 12).
(D) Effect of G-CSF on the percentage of NKX2.5-
positive cells in hiPSCs (n = 5).
(E) Quantitative RT-PCR for cardiac markers such
as NKX2.5, TBX5, MYL2, MYH6, and NPPA. Note
that all cardiac markers showed strong enhance-
ment of there expression levels (n = 7).
(F) Immunofluorescent stainings of the cardiac
marker proteins including a-Actinin, Troponin C,
NKX2.5, and ANP in the control and G-CSF-
treated hiPSC-derived EBs. Note that cardiomyo-




G-CSF Promotes Cardiomyocyte Proliferationproliferation protocol. We thought these factors would synergis-
tically regulate cardiomyocyte proliferation with other factors.
However, the requirement for multiple factors has hampered
research into regenerative medicine approaches to controlling
cardiomyocyte proliferation. We therefore had to search for
other potent and useful cardiomyocyte proliferating factors.
G-CSF was cloned in 1986 (Souza et al., 1986) and was
considered to be a hematopoietic cytokine that stimulated the
growth of neutrophil colonies (Welte et al., 1996). csf3r–/– mice
have chronic neutropenia, granulocyte and macrophage
progenitor cell deficiencies, and impaired neutrophil mobiliza-
tion (Lieschke et al., 1994). To date, research has not focused
on the role of G-CSF in development because although approx-
imately 50% of csf3r–/– mice die during embryogenesis because
of heart defects, the surviving mice grow to adulthood. The heart
defects seen in csf3r–/– mice indicate that G-CSF might play a
critical role in cardiomyocyte proliferation, although there is a
possibility that lack of G-CSFR in the hematopoietic or other
type of cells may indirectly affect its results. Interestingly, G-
CSF also affects the adult heart. It promotes adult cardiac
regeneration by mobilizing bone marrow mesenchymal stem
cells (Kawada et al., 2004) and prevents left ventricular remodel-234 Cell Stem Cell 6, 227–237, March 5, 2010 ª2010 Elsevier Inc.ing after myocardial infarction by
reducing cardiomyocyte apoptosis (Har-
ada et al., 2005).
Based on our previous results in the
developing heart, we investigated the
possible role of G-CSF in cardiac devel-
opment and ESC differentiation. Our
results demonstrated that both G-CSF
and its receptor are strongly expressed
in the embryonic heart and that G-CSFis critically involved in cardiomyocyte proliferation during devel-
opment. G-CSF increased the number of ESC-derived cardio-
myocytes in not only mouse but also common marmoset
monkey ESCs, indicating that this phenomenon is applicable
to primate ESCs and is potentially universal. Human ESCs are
not easy to handle.We propose that efforts in regenerativemedi-
cine with human ESC-derived cardiomyocytes might therefore
benefit from G-CSF treatment to boost cardiomyocyte yield
from ESCs, possibly in combination with other cardiomyocyte
differentiation protocols.EXPERIMENTAL PROCEDURES
Whole-Mount In Situ Hybridization
Murine embryos were removed from thewild-type ICRpregnantmice on embry-
onic days 7.5, 8.5, 9.5, and 10.5. Whole-mount in situ hybridization was per-
formed as described (Yuasa et al., 2005) utilizing ULTRAhyb (#8670, Ambion,
Austin, TX). The full-length cDNAs for murine nkx2.5 (accession number
NM_008700)wereobtained byRT-PCRand subcloned into pBluescript plasmid,
and the probes were generated with T3 or T7 RNA polymerase. A plasmid sub-
cloning murine csf3r (g-scfr) was a kind gift from Prof. S. Nagata (Department
of Genetics, Osaka University) (Fukunaga et al., 1990). All experiments were
approved by the Keio University Ethics Committee for Animal Experiments.
Cell Stem Cell
G-CSF Promotes Cardiomyocyte ProliferationESC Culture
Undifferentiated murine ESCs (EB3) were maintained on gelatin-coated dishes
in GMEM containing 10% FBS (Equitechbio, Ingram, TX), 2 mM L-glutamine,
0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM 2-mercap-
toethanol, and 2000 U/ml murine LIF (Chemicon International, Temecula, CA).
EB3 cells were a kind gift from H. Niwa (Riken, Japan) (Niwa et al., 2000). EB3
cells carry the blasticidin S-resistance gene, which is activated by the Oct3/4
promoter to eliminate differentiated cells. EB3 cells were maintained in
medium containing 20 mg/ml blasticidin S. EB3 is a subline derived from
E14tg2a ESCs and was generated by targeted integration of the Oct3/4-
IRES-BSD-pA vector into the Oct3/4 allele.
Differentiation of ESCs
Maintained undifferentiated ESCs were trypsinized and cultured with a three-
dimensional culture system in a-MEMcontaining 10%FBS and 0.1mM2-mer-
captoethanol on uncoated Petri dishes to induce embryoid bodies (EBs) from
a single cell. Recombinant murine G-CSF (414-CS, R&D Systems, Minneapo-
lis, MN) was added on prescribed days. Signal inhibition analysis was
performed by administering G-CSFR neutralizing antibody (AF-414-NA, R&D
Systems) 5 days after the differentiation induction. In the mitosis inhibition
assay, 0.2 mg/ml of nocodazole, 30 mg/ml of roscovitine (487928 and
557360, respectively, Calbiochem, Tokyo, Japan), and 5 mg/ml of aphidicolin
(Wako, Osaka, Japan) was administered 6 days after the differentiation induc-
tion, simultaneously with the addition of G-CSF.
csf3r–/– Mice
csf3r–/–mice (G-CSFR KOmice) were a kind gift from Dr. Daniel C. Link (Wash-
ington University School of Medicine, St. Louis) (Richards et al., 2003).
Morphological Analysis
G-CSF or PBS (negative control) was injected into the uterus of the pregnant
wild-type and csf3r–/– mice at E9.5 (n = 10, respectively). Mice were sacrificed
at E16.5 (n = 5) or P1 (n = 5) and the hearts were removed and analyzed by
sectioning and staining with hematoxylin and eosin.
Common Marmoset ESC Culture
The commonmarmoset ESC (CMESC) line (#20) (Sasaki et al., 2005) was used
in this study. CMESCs were maintained on a layer of mitotically inactivated
mouse embryonic fibroblasts (MEF) in Knockout DMEM (GIBCO) supple-
mented with 20% Knockout Serum Replacement (KSR; GIBCO), 1 mM
L-glutamine (GIBCO), 0.1 mM MEM nonessential amino acids (GIBCO),
0.1 mM b-mercaptoethanol (2-ME; Sigma), 10 ng/ml basic fibroblast growth
factor (bFGF; Invitrogen), and 10 ng/ml human leukemia inhibitory factor
(hLIF; Alomone labs). CMESCs were passaged every 5 days to maintain their
undifferentiated state.
Differentiation of CMESCs
Undifferentiated CMESCs were removed from the MEF feeder layer, dissoci-
ated into small clumps with dissociation solution for human and monkey
ESCs (ReproCELL, JAPAN), and cultured to form EBs in suspension culture
with HydroCell culture plates (CellSeed, JAPAN) in culture medium without
bFGF and hLIF.
Human iPSC Culture
The hiPSC line 201B7 (Takahashi et al., 2007), into which Oct3/4, Sox2, Klf4,
and c-Mycwere retrovirally transfected, wasmaintained in the undifferentiated
state on a mitomycin C-inactivated MEF feeder layer in DMEM/F12 medium
(Invitrogen) supplemented with 20% Knock-out Serum Replacement (KSR),
1 mM l-glutamine, 1 mM nonessential amino acids, 0.1 mM b-mercaptoetha-
nol, and 4 ng/ml basic fibroblast growth factor (bFGF), as described previously
(Tanaka et al., 2009). The hiPSC culture medium was changed daily, and the
cells were passaged every 5–6 days.
Differentiation of Human iPSCs
The hiPSC colonies were dispersed into cell aggregates that contained 2000–
5000 cells via CTK dissociation solution. For differentiation, hiPS colonies of
appropriate size were chosen with a combination of 40 mm and 100 mm cell
strainers (Becton-Dickinson), which also facilitated the complete removal offeeder cells. The cell aggregates were cultured in suspension in ultralow
attachment cell culture dishes in hiPS differentiation medium (DMEM/F12 sup-
plemented with 20% FBS, 1 mM l-glutamine, 1 mM nonessential amino acids,
and 0.1mM b-mercaptoethanol), as described previously (Tanaka et al., 2009).
The EBswere incubated at 37C in 5%CO2. During differentiation, themedium
was replaced every 3–4 days. Recombinant human G-CSF (Wako 074-04841)
was administrated at a concentration of 2.5 ng/ml on day 6, and assay was
performed on day 30.
Immunofluorescence
EBs were fixed in 4% paraformaldehyde for 30 min and embedded for frozen
sectioning with Tissue-Tek OCT (Sakura Finetek, Chuoku, Tokyo) on day 10.
In some experiments, undifferentiated ESCs were fixed in 4% paraformalde-
hyde for 30 min and immunostained as described below. The samples were
incubated with Triton X-100 for 5 min at room temperature, then washed
and incubated with primary antibodies: anti-Nkx2.5 (N-19, 1:50), anti-MEF2C
(C-21, 1:100), anti-Troponin C (E-7, 1:50), anti-ANP (FL-153, 1:50), anti-G-
CSFR (H-176, 1:50), and anti-GCSF (E-19, 1:50) purchased from Santa Cruz
Biotechnology (Santa Cruz, CA); anti-a-Actinin (EA-53, 1:800) from Sigma (St.
Louis, MO); anti-ANP (1:100) from CHEMICON (Temecula, CA); anti-Actin
(HNF35) from NeoMarker (Fremont, CA); and anti-myosin heavy chain (MHC)
(MF20), a gift from David Bader. After overnight incubation, bound antibodies
were visualizedwith a secondary antibody conjugated to Alexa488 or Alexa546
(Molecular Probes,Minato-ku, Tokyo). Nucleiwere stainedwith 40,6-diamidine-
2-phenylidole dihydrochloride (DAPI; Sigma) or TO-PRO3 (Molecular Probes).
Quantitative RT-PCR
Total RNA was extracted with Trizol reagent (GIBCO, Minato-ku, Tokyo). RT-
PCRwas performed as described previously with the following primers (Yuasa
et al., 2005). gapdh was used as an internal control. For quantitative analysis
ofbrachyury T and nkx2.5 expression, cDNAwasused as the template in a Taq-
Man real-time PCR assay with the ABI Prism 7700 sequence detection system
(Applied Biosystems, Foster City, CA) according to themanufacturer’s instruc-
tions. All samples were run in triplicate. Data were normalized to gapdh. The
primers and TaqMan probe for murine brachyury T, nkx2.5, csf3, csf3r, gata4,
mlc2v, tbx5, and nppa rat csf3r were Mm00436877_m1, Mm00657783_m1,
Mm00438334_m1, Mm01179739_m1, Mm00484689_m1, Mm00440384_m1,
Mm00803521_m1, Mm011255747_g1, and Rn01516131_m1 (Applied Biosys-
tems), and primers and probes for human NPPA, TBX5, NKX2.5, MYH6, and
MYL2 were Hs00383230_g1, Hs01052563_m1, Hs00231763_m1,
Hs_00411908m1, and Hs_00166405m1, respectively.
Proliferation Assay
Pregnant mice were injected directly into the uterus with 7.5 ng of murine
G-CSF (414-CS, R&D Systems) on embryonic day 9.0. After G-CSF injection,
pregnant mice were injected intraperitoneally with BrdU (BrdU labeling kit;
1296 736 Roche, Basel, Switzerland) at embryonic day 9.5. Mice were sacri-
ficed at embryonic day 12.5, when embryos were removed and prepared
for fresh frozen sectioning. After antigen retrieval with histoVT One (L6F9587
Nacalai Tesque, Nakagyoku, Kyoto) and blocking, BrdU was stained as
described in the protocol. Phospho-histone H3 staining was also performed
with a specific primary antibody (#9701, Cell Signaling Technology, Danvers,
MA) as described above. MEF2C and BrdU double staining was performed
with MEF2C antibody (C-21, Santa Cruz; 1:100). TheMEF2C signal was ampli-
fied with biotinylated anti-rabbit antibody (Jackson Immunoresearch, 711-
065-152; 1:500), VECTASTAIN Elite ABC kit (PK-6200, VECTOR laboratories;
1:100), and TSA Fluorescence systems (NEL702, 1:50).
Small Interfering RNAs and Transfections
Knockdown of proteins was performed with Silencer Select Pre-designed
siRNA (Applied Biosystems) with the following IDs: JAK2 siRNA1, s68539;
JAK2 siRNA2, s68540; STAT3 siRNA1, s74451; and STAT3 siRNA2, s20848.
Transfection of siRNAs was performed with siPORTNeoFX Transfection agent
(Applied Biosystems).
Explant Culture
E9.0 embryonic hearts were removed and cultured in serum-free a-MEM.
Recombinant murine G-CSF, mitotic inhibitors, and BrdU were added at theCell Stem Cell 6, 227–237, March 5, 2010 ª2010 Elsevier Inc. 235
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after 2 days of culture. Mitotic inhibitors used in the assay were 50 mM of
JAK2 inhibitor AG490 (658401, Cosmobio, Kotoku, Tokyo), 100 mM of
STAT3 inhibitor peptide, 5 mM of MEK1/2 inhibitor, 10 mM of JNK inhibitor,
20 mM of Akt inhibitor, and 10 mM of p38 inhibitor SB203580 (573096,
444939, 420119, 124005, and 559389, respectively, Calbiochem, Meguroku,
Tokyo). Immunostaining of BrdU was performed as described above.
TUNEL Assay
G-CSF was injected in to the uterus of pregnant mice at E9.0, and embryos
were removed at E12.5 or E16.5. TUNEL staining was performed with the
in situ apoptosis detection kit (TAKARA, MK500) according to the manufac-
turer’s instruction.
Purification of Cardiomyocytes
Purification of cardiomyocyteswas performed as described previously (Hattori
et al., 2010).
Statistical Analysis
Data were analyzed with StatView J-4.5 software. Values are reported as
means ± SD. Comparisons among groups were performed by one-way
ANOVA. Scheffe’s F test was used to determine level of significance. The prob-
ability level accepted for significance was p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/j.
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